BPMC — Blueprint Medicines Share News
0.000.00%
Last trade - 00:00- $8.37bn
- $8.18bn
- $508.82m
Brief: Blueprint Medicines Corp Q4 Revenue $38.8 Million
Brief: Blueprint Medicines Reports Fourth Quarter And Full Year 2022 Results
Blueprint Medicines Corp expected to post a loss of $2.65 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ralph Lauren, J.M. Smucker, Lions Gate
U.S. STOCKS ON THE MOVE-Silvergate Capital, PayPal, Spotify
Blueprint Medicines Corp expected to post a loss of $2.64 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cloudflare, Coursera, Corsair Gaming
Blueprint Medicines falls as FDA puts partial hold on cancer drug trial
Brief: Blueprint Medicines Announces Partial Clinical Hold For Phase 1/2 VELA Trial Of BLU-222
U.S. FDA puts partial hold on Blueprint Medicines cancer drug trial (updated)
U.S. FDA puts Blueprint Medicines' cancer drug trial on partial hold
Brief: Blueprint Medicines Announces FDA Acceptance Of Supplemental New Drug Application For AYVAKIT® (Avapritinib) For The Treatment Of Indolent Systemic Mastocytosis
Brief: Blueprint Medicines Provides 2023 Portfolio Goals
Brief: Blueprint Medicines Reports Clinical Data In Developing Targeted Treatment Options For Patients With Systemic Mastocytosis
U.S. STOCKS ON THE MOVE-Uniqure, BioMarin, Blueprint Medicines
Blueprint Medicines rises on FDA submission for bone-marrow disease drug
Brief: Blueprint Medicines Submits Supplemental New Drug Application To FDA For Ayvakit (Avapritinib) For Treatment Of Indolent Systemic Mastocytosis
U.S. RESEARCH ROUNDUP-Avista, IPG Photonics, Seaspine Holdings
Blueprint Medicines Corp reports results for the quarter ended in September - Earnings Summary